资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
map
#百时美#
60篇内容 | 2160人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=8fe0e188265, topicName=百时美, introduction=百时美, content=null, image=null, comments=60, allHits=2160, url=https://h5.medsci.cn/topic?id=71882, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=25996, tagList=[TagDto(tagId=25996, tagName=百时美)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1764438, encodeId=a4621e644389e, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=PD-1免疫疗法监管重大里程碑:百时美Opdivo获欧盟批准,系欧洲PD-1疗法, objectType=article, longId=52397, objectId=b2135239e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2135239e88, replyNumber=0, likeNumber=91, createdTime=2015-10-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2135239e88, moduleTitle=PD-1免疫疗法监管重大里程碑:百时美Opdivo获欧盟批准,系欧洲PD-1疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b2135239e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764436, encodeId=25661e644368c, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy, objectType=article, longId=48622, objectId=13964862214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13964862214, replyNumber=0, likeNumber=71, createdTime=2015-09-27, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13964862214, moduleTitle=默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=13964862214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764435, encodeId=e86b1e64435a1, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=FDA受理百时美黑色素瘤药物Yervoy sBLA,或成20年来辅助治疗新选择, objectType=article, longId=47718, objectId=404a4e718e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=404a4e718e7, replyNumber=0, likeNumber=65, createdTime=2015-04-02, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=404a4e718e7, moduleTitle=FDA受理百时美黑色素瘤药物Yervoy sBLA,或成20年来辅助治疗新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=404a4e718e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764433, encodeId=dd001e6443365, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, objectType=article, longId=44001, objectId=f44c44001b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f44c44001b8, replyNumber=0, likeNumber=63, createdTime=2015-02-21, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f44c44001b8, moduleTitle=PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f44c44001b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764432, encodeId=759a1e64432d8, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%, objectType=article, longId=39744, objectId=afa239e4413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa239e4413, replyNumber=0, likeNumber=67, createdTime=2015-07-09, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa239e4413, moduleTitle=吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=afa239e4413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764434, encodeId=2c1d1e644341b, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=PD-1领域的合纵连横,默沙东、百时美分别与礼来合作, objectType=article, longId=45585, objectId=d25945585ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d25945585ce, replyNumber=0, likeNumber=71, createdTime=2015-10-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d25945585ce, moduleTitle=PD-1领域的合纵连横,默沙东、百时美分别与礼来合作, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d25945585ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764429, encodeId=4e0a1e64429ee, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%, objectType=article, longId=33222, objectId=bfe733222a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe733222a0, replyNumber=0, likeNumber=71, createdTime=2014-07-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe733222a0, moduleTitle=百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bfe733222a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764428, encodeId=96621e644287f, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美向FDA提交丙肝新药NDA, objectType=article, longId=33002, objectId=badb33002f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=badb33002f3, replyNumber=0, likeNumber=63, createdTime=2014-11-25, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=badb33002f3, moduleTitle=百时美向FDA提交丙肝新药NDA, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=badb33002f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物, objectType=article, longId=35568, objectId=2a283556847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a283556847, replyNumber=0, likeNumber=82, createdTime=2015-02-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a283556847, moduleTitle=百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a283556847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764424, encodeId=1deb1e6442441, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准, objectType=article, longId=29872, objectId=6f49298e2c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f49298e2c4, replyNumber=0, likeNumber=73, createdTime=2014-07-30, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f49298e2c4, moduleTitle=阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6f49298e2c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764426, encodeId=f9221e6442622, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效, objectType=article, longId=31687, objectId=517d3168e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=517d3168e03, replyNumber=0, likeNumber=59, createdTime=2014-04-13, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=517d3168e03, moduleTitle=百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=517d3168e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764425, encodeId=da251e644254b, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美计划启动免疫组合疗法大型III期试验, objectType=article, longId=31582, objectId=6842315820e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6842315820e, replyNumber=0, likeNumber=60, createdTime=2014-06-23, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6842315820e, moduleTitle=百时美计划启动免疫组合疗法大型III期试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6842315820e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764430, encodeId=f7f71e6443079, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%, objectType=article, longId=33503, objectId=8e5c33503d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5c33503d1, replyNumber=0, likeNumber=68, createdTime=2014-08-28, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5c33503d1, moduleTitle=百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8e5c33503d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764427, encodeId=ce911e6442730, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美及辉瑞艾乐妥(Eliquis) sNDA获FDA批准, objectType=article, longId=31979, objectId=bec4319e9ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec4319e9ae, replyNumber=0, likeNumber=82, createdTime=2014-03-27, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec4319e9ae, moduleTitle=百时美及辉瑞艾乐妥(Eliquis) sNDA获FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bec4319e9ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764422, encodeId=50d21e6442261, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美在日本提交HCV全口服方案新药申请, objectType=article, longId=26221, objectId=84af2622184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84af2622184, replyNumber=0, likeNumber=58, createdTime=2014-03-06, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84af2622184, moduleTitle=百时美在日本提交HCV全口服方案新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=84af2622184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764423, encodeId=78a41e64423f0, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo, objectType=article, longId=27142, objectId=6f712e142a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f712e142a5, replyNumber=0, likeNumber=66, createdTime=2014-09-29, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f712e142a5, moduleTitle=CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6f712e142a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764421, encodeId=bdb31e64421d0, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, objectType=article, longId=23002, objectId=c9752300260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9752300260, replyNumber=0, likeNumber=67, createdTime=2014-03-24, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9752300260, moduleTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9752300260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764420, encodeId=0d3d1e64420af, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请(sNDA), objectType=article, longId=21572, objectId=b9d4215e217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d4215e217, replyNumber=0, likeNumber=70, createdTime=2014-01-12, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d4215e217, moduleTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请(sNDA), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b9d4215e217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764418, encodeId=56421e64418ff, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, objectType=article, longId=3703, objectId=39fd3e036a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39fd3e036a, replyNumber=0, likeNumber=74, createdTime=2012-02-22, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39fd3e036a, moduleTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39fd3e036a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764419, encodeId=dc0c1e64419a8, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效, objectType=article, longId=5773, objectId=83145e7385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83145e7385, replyNumber=0, likeNumber=69, createdTime=2012-07-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83145e7385, moduleTitle=百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=83145e7385)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
百时美
2020-05-29
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
PD-1免疫疗法监管重大里程碑:百时美Opdivo获欧盟批准,系欧洲PD-1疗法
91
0
2015-10-18
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy
71
0
2015-09-27
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
FDA受理百时美黑色素瘤药物Yervoy sBLA,或成20年来辅助治疗新选择
65
0
2015-04-02
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab
63
0
2015-02-21
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%
67
0
2015-07-09
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
PD-1领域的合纵连横,默沙东、百时美分别与礼来合作
71
0
2015-10-18
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%
71
0
2014-07-18
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美向FDA提交丙肝新药NDA
63
0
2014-11-25
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物
82
0
2015-02-18
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准
73
0
2014-07-30
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效
59
0
2014-04-13
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美计划启动免疫组合疗法大型III期试验
60
0
2014-06-23
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%
68
0
2014-08-28
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美及辉瑞艾乐妥(Eliquis) sNDA获FDA批准
82
0
2014-03-27
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美在日本提交HCV全口服方案新药申请
58
0
2014-03-06
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo
66
0
2014-09-29
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美施贵宝抑郁药BMS-820836 II期试验失败
67
0
2014-03-24
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请(sNDA)
70
0
2014-01-12
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美施贵宝25亿美元收购丙肝药商Inhibitex
74
0
2012-02-22
回复
ms1467340776200723
(审核中...)
关注
已关注
前往app查看评论内容
#百时美#
百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效
69
0
2012-07-15
回复
共60条
首页
上一页
下一页
尾页
页码:
3
/3页
20条/页
扫描二维码下载梅斯医学APP
map
科室
订阅+
更多科室
工具
服务
map
map